2Pearson TA;Mensah GA;Alexander RW.Markers of inflammation and cardiovascular disease,application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J],2003.
3Danesh J;Wheeler JG;Hirschfield GM.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J],2004(14).
4Yasojima K;Schwab C;McGeer EG.Generation of C-reactive Protein and complement components in atherosclerotic plaques[J],2001(10).
6Yip HK;Hung WC;Yang CH.Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting[J],2005(10).
7Zairis MN;Ambrose JA;Ampartzidou O.Preprocedural plasma C-reactive Protein levels,post procedural creatinekinase-MB release,and long-term Prognosis after successful coronary stenting[J],2005.
10Balistreri CR;Vasto S.Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily:a pilot study[J],2006.
4[1]Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA,2001,285: 2370-2375.
5[2]Benjamin E J, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA, 1994,271: 840-844.
6[3]Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med,1982,306: 1018-1022.
7[4]Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the puhmonary veins.N Engl J Med, 1998,339: 659-666.
8[5]Psychari SN, Apostolou TS, Sinos L , et al. Relation of elevated Creactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol, 2005,95 :764-767.
9[6]Watanabe T. Takeishi Y, Hirono O, et al. C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients witb paroxysmal atrial fibrillation. Heart Vessels ,2005,20:45-49.
10[7]Aviles R J, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for atrial fibrillation. Circulation,2003,108:3006-3010.
3Song ZF, Ji XP, Li XX, et al. Inhibition of the activity of Poly (ADP - Ribose) Polymerase reduces heart ischemia/repeffusion injury via suppressing JNK mediated AIF translocation [ J ]. J Cell Mol Med, 2008,12(4) : 1220 - 1228.
4Wang SJ, Wang SH, Song ZF, et 81. Poly(ADP- ribose) polymer- ase inhibitor is neuroprotective in epileptic rat via apoptosis - indu- cing factor and Akt signaling[ J ]. Neuroreport,2007,18 ( 12 ) : 1285 - 1289.
5Celik - Ozenci C, TasatargiI A, Tekcan M, ctal. Effects of abam- ectin exposure on male fertility in rats: potential role of oxidative stress - mediated poly( ADP - ribose) polymerase (PARP) activa- tion[ J]. Regal Toxicol Pharmaco1,2011,61 ( 3 ) :310 - 317.
6Min W, Wang ZQ. Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential[J]. Front Biosci,2009,14(9) :1619 - 1626.
7Javle M, Curtin NJ. The role of PARP in DNA repair and its thera- peutic exploitation[J]. Br J Cancer,2011,105(8) :1114 -1122.
8Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies[J]. Am J Cancer Res,2011,1 (3) : 301 - 327.
